ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,213.49
0.51%
Dow Jones
38,825.17
0.39%
Gold vs US Dollar
2,329.23
1.54%
Brent Oil
83.395
0.32%
Bitcoin
64,114.22
0.17%
Pepperstone
Advertisement
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Akero Therapeutics Inc (AKRO)

  7. Akero Therapeutics Inc (AKRO) News

Akero Therapeutics (AKRO)

Akero Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:AKRO
DateTimeSourceHeadlineSymbolCompany
30/04/202413:00GlobeNewswire Inc.Akero Therapeutics Appoints Scott Gangloff as Chief Technology OfficerNASDAQ:AKROAkero Therapeutics Inc
08/03/202421:02GlobeNewswire Inc.Akero Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional SharesNASDAQ:AKROAkero Therapeutics Inc
07/03/202421:01GlobeNewswire Inc.Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Cohort D Study in Clinical Gastroenterology and HepatologyNASDAQ:AKROAkero Therapeutics Inc
07/03/202401:14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AKROAkero Therapeutics Inc
07/03/202401:13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AKROAkero Therapeutics Inc
06/03/202422:25Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AKROAkero Therapeutics Inc
06/03/202422:16Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:AKROAkero Therapeutics Inc
06/03/202402:13GlobeNewswire Inc.Akero Therapeutics Announces Pricing of Public Offering of Common StockNASDAQ:AKROAkero Therapeutics Inc
05/03/202422:16Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AKROAkero Therapeutics Inc
05/03/202411:05IH Market NewsAMD Hits Regulatory Roadblock, GitLab’s Stock Tumbles on Disappointing Earnings, and Latest NewsNASDAQ:AKROAkero Therapeutics Inc
04/03/202422:34Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AKROAkero Therapeutics Inc
04/03/202422:30Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AKROAkero Therapeutics Inc
04/03/202422:21Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:AKROAkero Therapeutics Inc
04/03/202421:21GlobeNewswire Inc.Akero Therapeutics Announces Proposed Public Offering of Common StockNASDAQ:AKROAkero Therapeutics Inc
04/03/202412:55Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AKROAkero Therapeutics Inc
04/03/202411:00GlobeNewswire Inc.Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY StudyNASDAQ:AKROAkero Therapeutics Inc
29/02/202421:42Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:AKROAkero Therapeutics Inc
29/02/202413:00GlobeNewswire Inc.Akero Therapeutics to Present Topline Week 96 Results from Phase 2b HARMONY Study Investigating Efruxifermin in Patients with Pre-Cirrhotic MASHNASDAQ:AKROAkero Therapeutics Inc
29/02/202412:30Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:AKROAkero Therapeutics Inc
29/02/202412:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AKROAkero Therapeutics Inc
29/02/202412:00GlobeNewswire Inc.Akero Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:AKROAkero Therapeutics Inc
14/02/202402:40Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:AKROAkero Therapeutics Inc
03/01/202422:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AKROAkero Therapeutics Inc
03/01/202413:15GlobeNewswire Inc.Akero Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:AKROAkero Therapeutics Inc
30/12/202301:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AKROAkero Therapeutics Inc
29/12/202323:07Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AKROAkero Therapeutics Inc
19/12/202301:49Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AKROAkero Therapeutics Inc
19/12/202301:40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AKROAkero Therapeutics Inc
19/12/202301:39Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AKROAkero Therapeutics Inc
19/12/202301:37Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AKROAkero Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:AKRO

Your Recent History

LSE
POS
Plexus
LSE
RR.
Rolls-royce
LSE
HUM
Hummingbird Resources
LSE
SBTX
Skinbiotherapeutics
LSE
SRSP
Sirius Petroleum
LSE
AAU
Ariana Resources
LSE
BIRD
Blackbird
LSE
SCE
Surface Transforms
LSE
AGL
Angle
LSE
LLOY
Lloyds Banking
LSE
ENET
Ethernity Networks
LSE
SOLG
Solgold
LSE
GFM
Griffin Mining
LSE
ASC
Asos
LSE
SCLP
Scancell
LSE
OBI
Ondine Biomedical
Delayed Upgrade Clock
    ADVFN Logo

    United Kingdom
    Company
    Business
    Popular
    Get The App

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved